p53 Nongenotoxic Activation and mTORC1 Inhibition Lead to Effective Combination for Neuroblastoma TherapyMyrthala Moreno‐Smith, Eveline Barbieri, Anna Lakoma et al.|Clinical Cancer Research|2017Cited by 25
Supplementary Figure 5 from p53 Nongenotoxic Activation and mTORC1 Inhibition Lead to Effective Combination for Neuroblastoma TherapyMyrthala Moreno‐Smith, Eveline Barbieri, Anna Lakoma et al.|Unknown|2023Cited by 0
Supplementary Figure 3 from p53 Nongenotoxic Activation and mTORC1 Inhibition Lead to Effective Combination for Neuroblastoma TherapyMyrthala Moreno‐Smith, Eveline Barbieri, Anna Lakoma et al.|Unknown|2023Cited by 0
Supplementary Figure 8 from p53 Nongenotoxic Activation and mTORC1 Inhibition Lead to Effective Combination for Neuroblastoma TherapyMyrthala Moreno‐Smith, Eveline Barbieri, Anna Lakoma et al.|Unknown|2023Cited by 0
Supplementary Figure 1 from p53 Nongenotoxic Activation and mTORC1 Inhibition Lead to Effective Combination for Neuroblastoma TherapyMyrthala Moreno‐Smith, Eveline Barbieri, Anna Lakoma et al.|Unknown|2023Cited by 0